Atossa Therapeutics宣布了一项监管策略,该策略旨在加速推进低剂量(Z)-恩多昔芬在乳腺癌风险降低方面的药物开发进程。
Atossa Therapeutics宣布了一项监管策略,该策略旨在加速推进低剂量(Z)-恩多昔芬在乳腺癌风险降低方面的药物开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.